- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01742195
Comparison of Patient Comfort With the Nasal and Oral Insertion of the Endobronchial Ultrasound Bronchoscope
Randomized Study Comparing the Oral and Nasal Routes for Linear Endobronchial Ultrasound
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Linear endobronchial ultrasound (EBUS) now plays a crucial role in the diagnosis, staging, and treatment planning of lung cancer. Most centers perform linear EBUS via the oral route given the larger diameter of the bronchoscope used. However, the feasibility and the diagnostic accuracy of linear EBUS performed through the nose have not been reported. Furthermore, the two routes of insertion have never been compared in terms of patient satisfaction and comfort.
In order to compare the two routes of insertion, consecutive patients referred for a linear endobronchial ultrasound will be recruited. Participants will be randomized to either oral or nasal insertion. All participants will be sedated and will receive local anesthetics in a similar manner. After the procedure, patients will fill a questionnaire regarding their comfort and satisfaction with the procedure.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4G5
- Institut Universitaire de cardiologie et de pneumologie de Quebec
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- patients older than 18 years of age
- patients referred for a first linear endobronchial ultrasound
Exclusion Criteria:
- Patients who previously underwent an EBUS
- Patients intubated with an endotracheal tube
- Patients under the age of 18
- Patients unable to provide informed consent
- Patients currently taking anticoagulants (therapeutic doses of intravenous or subcutaneous heparin, low-molecular weight heparins, direct thrombin inhibitors or other agents)
- Patients taking anti-platelet therapy other than aspirin (clopidogrel, ticagrelor, prasugrel). A period of 7 days off medication is required before participation.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Nasal EBUS insertion
Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
|
|
|
Ander: Oral EBUS insertion
Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Patient comfort and satisfaction
Tijdsspanne: Two hours after endobronchial ultrasound
|
Measured by a questionnaire using a 10-point Likert scale for both comfort and satisfaction.
|
Two hours after endobronchial ultrasound
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Physician's assessment of patient comfort
Tijdsspanne: Immediately after the procedure (within 10 minutes)
|
Measured by a questionnaire using a 10-point Likert scale regarding patient comfort and procedural difficulties.
|
Immediately after the procedure (within 10 minutes)
|
|
Duration of endobronchial ultrasound procedure
Tijdsspanne: During the procedure
|
Measured in minutes.
|
During the procedure
|
|
Total doses of sedation
Tijdsspanne: Immediately after the procedure (within 10 minutes)
|
Total doses of each sedative used will be recorded.
|
Immediately after the procedure (within 10 minutes)
|
|
Occurence of pneumothorax, bleeding more than 50ml, oxygen desaturation to less than 90%, epistaxis, cardiac arrhythmia
Tijdsspanne: During the procedure and up to two hours after
|
During the procedure and up to two hours after
|
|
|
Proportion of adequate cytology specimens in each group
Tijdsspanne: Days after the procedure (results usually available within 10 days)
|
Days after the procedure (results usually available within 10 days)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Stéphane Beaudoin, MD, Laval University
- Hoofdonderzoeker: Simon Martel, MD, Laval University
- Hoofdonderzoeker: Antoine Delage, MD, Laval University
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- IUCPQ-20871
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .